To Be Discontinued Injection Oncology
Oxaliplatin Injection · 326 days since initial FDA posting
Brand: OXALIPLATIN
FDA lists Oxaliplatin Injection as To Be Discontinued (Sandoz Inc.).
No availability text on this FDA row.
Oxaliplatin Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Oxaliplatin Injection
- Manufacturer
- Sandoz Inc.
- Dosage Form
- Injection
- Presentation
- Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80)
- Package NDC
- 0781-3317-80
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Oct 20, 2025
- Last Updated
- Oct 20, 2025
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Oxaliplatin Shortage Records
Oxaliplatin Injection
Sandoz Inc.
Injection
Oxaliplatin Injection
Novast Labs
Injection
Oxaliplatin Injection
Novast Labs
Injection
Oxaliplatin Injection
Fresenius Kabi USA, LLC
Injection
Oxaliplatin Injection
Fresenius Kabi USA, LLC
Injection
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.